Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib

Posted by rob on May 31, 2010 under Uncategorized | Comments are off for this article

Abstract  We investigated the efficacy of the induction therapy involving granulocyte colony-stimulating factor (G-CSF) and low-dose
homoharringtonine as well as standard-dose imatinib, which we called the G-CSF?+?homoharringtonine?+?imatinib (GHI) regimen,
in patients with chronic myelogenous leukemia (CML) in blast crisis who have failed prior single-agent therapy with imatinib.
Twelve patients were enrolled. The GHI regimen consisted in a unique induction course where imatinib was administered at 400 mg day?1 until remission, together with homoharringtonine (1 mg/m2?s.c. twice daily for 14 days every 28 days), and G-CSF, which was administered 1 day before chemotherapy (5 µg/kg s.c. daily).
Patients who failed to obtain …
More